Summit Therapeutics PLC Sponsored ADR Stock

$28.67

3.99% day before yesterday

Nasdaq, Jul 25, 10:07 pm CET

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Summit Therapeutics PLC Sponsored ADR Stock price

$28.67

+24.87 654.47% 5Y

Nasdaq, Closing price Fri, Jul 25 2025

+1.10 3.99%

ISIN

US86627R1023

Symbol

SMMT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$21.3b

Enterprise Value

$20.9b

Net debt

positive

Cash

$361.3m

Shares outstanding

741.6m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

61.8

Financial Health

Equity Ratio

89.3%

Return on Equity

-56.9%

ROCE

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

- | $0.0

EBITDA

- | $-315.7m

EBIT

- | $-323.3m

Net Income

- | $-302.2m

Free Cash Flow

$-173.7m

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Summit Therapeutics PLC Sponsored ADR Stock Analysis

Unlock Scores for Free

??

17 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

15x Buy

88%

More details on Analyst Estimates Including Price Targets

17 Analysts have issued a Summit Therapeutics PLC Sponsored ADR forecast:

Buy

88%

Hold

Sell

Analyst Estimates with Stock Price Targets

Financial data from Summit Therapeutics PLC Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	49 49	61% 61% -
- Research and Development Expense	120 120	79% 79% -
EBITDA	-169 -169	72% 72% -
- Depreciation and Amortization	0.09 0.09	55% 55% -
EBIT (Operating Income) EBIT	-169 -169	72% 72% -
Net Profit	-178 -178	71% 71% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Summit Therapeutics PLC Sponsored ADR Stock News

Positive

The Motley Fool

●

5 days ago

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts.

Positive

The Motley Fool

●

6 days ago

This Healthcare Stock's Revolutionary Drug Could Make Early Investors Rich

Three years ago, Summit Therapeutics (SMMT 1.26%) was a little-known small-cap biotech that few investors with an average tolerance for risk would have bothered to pay attention to at the time. However, the company's shares have skyrocketed by more than 2,000% since then.

Positive

The Motley Fool

●

7 days ago

3 Monster Stocks in the Making to Buy Right Now

Where can you find the next monster stocks? Check out the biotech space.

More Summit Therapeutics PLC Sponsored ADR News

Company Profile

Summit Therapeutics Plc operates as a holding company, which engages in the discovery, development, and commercialization of antibiotic medicines. The company operates through the Drug Development segment, which covers its research and development activities carried out by the Group. Summit Therapeutics was founded by Stephen Graham Davies and Kay Dame Davies in January 2003 and is headquartered in Abingdon, the United Kingdom.

Head office	United Kingdom
CEO	Robert Zanganeh
Employees	159
Founded	2003
Website	www.smmttx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now